Vanda Pharmaceuticals Inc.
VNDA
$4.92
-$0.10-1.99%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.97% | 5.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.97% | 5.09% | |||
| Cost of Revenue | 7.97% | -22.29% | |||
| Gross Profit | 6.92% | 7.17% | |||
| SG&A Expenses | -6.72% | 29.02% | |||
| Depreciation & Amortization | 0.06% | -0.06% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.90% | 0.03% | |||
| Operating Income | 18.75% | 6.15% | |||
| Income Before Tax | 18.62% | 6.64% | |||
| Income Tax Expenses | 24.43% | 2.46% | |||
| Earnings from Continuing Operations | 16.98% | 7.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.98% | 7.75% | |||
| EBIT | 18.75% | 6.15% | |||
| EBITDA | 19.88% | 6.56% | |||
| EPS Basic | 17.13% | 8.47% | |||
| Normalized Basic EPS | 18.75% | 7.37% | |||
| EPS Diluted | 17.13% | 8.47% | |||
| Normalized Diluted EPS | 18.75% | 7.37% | |||
| Average Basic Shares Outstanding | 0.17% | 0.80% | |||
| Average Diluted Shares Outstanding | 0.17% | 0.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||